RecruitingNCT06088134
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
Urology Department of the First Affiliated Hospital of Chongqing Medical University
Sponsor
Mingzhao Xiao
Enrollment
800 participants
Start Date
Sep 1, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's predictive ability with traditional models.
Eligibility
Inclusion Criteria3
- underwent partial/radical nephrectomies
- histologically diagnosed as ccRCC
- with complete clinical data and preoperative CT image data
Exclusion Criteria4
- with incomplete clinic-pathological data
- lack of preoperative contrast-enhanced CT images or the image quality was unsuitable for analysis
- who received pre-surgery neoadjuvant or adjuvant therapies
- with multiple renal tumors or/and had synchronous metastasis
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06088134
Related Trials
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
NCT068633112 locations
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT074696831 location
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
NCT073002417 locations
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
NCT0543314223 locations
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720399 locations